Impact of surgical optimality on the survival for patients diagnosed with clear cell carcinoma of ovary: a propensity score analysis with long-term follow-up

Purpose of Investigation: The authors aimed to investigate the impact of surgical optimality on clear cell carcinoma (CCC) versus serous adenocarcinoma of ovary (SAC). Materials and Methods: A retrospective analysis of a prospectively collected healthcare database in a single institution, recruiting consecutive patients diagnosed with Stage III epithelial ovarian cancer between January 2001 and December 2010, was conducted. Results: For optimal disease, median overall survival (95% confidence interval) was 57.1 (42.5−78.6) months for SAC and 52.6 (35.3−61.1) months for CCC, respectively (hazard ratio = 1.28, p = 0.222). For suboptimal disease, the corresponding value was 43.3 (36.5−58.2) months for SAC and 24.6 (21.9−37.1) months for CCC, respectively (hazard ratio = 2.33, p < 0.001). Conclusion: For optimal residual disease, CCC shows equal survival to SAC, while for suboptimal residual disease, CCC still shows very dismal outcome compared to SAC, suggesting the urgent need to test novel drugs to treat this subset of patients.

Ovarian cancer; Clear cell carcinoma; Serous carcinoma; Optimal disease.

[1] Heintz A.P., Odicino F., Maisonneuve P., Quinn M.A., Benedet J.L., Creasman W.T., et al.: “Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer”. Int. J. Gynaecol. Obstet., 2006, 95, S161.

[2] Kennedy A.W., Markman M., Biscotti C.V., Emery J.D., Rybicki L.A.: “Survival probability in ovarian clear cell adenocarcinoma”. Gynecol. Oncol., 1999, 74, 108.

[3] Recio F.O., Piver M.S., Hempling R.E., Driscoll D.L.: “Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy”. Cancer, 1996, 78, 2157.

[4] Behbakht K., Randall T.C., Benjamin I., Morgan M.A., King S., Rubin S.C.: “Clinical characteristics of clear cell carcinoma of the ovary”. Gynecol. Oncol., 1998, 70, 255.

[5] Jin Y., Li Y., Pan L.: “The target therapy of ovarian clear cell carcinoma”. Onco. Targets Ther., 2014, 7, 1647.

[6] Godwin A.K., Meister A., O’Dwyer P.J., Huang C.S., Hamilton T.C., Anderson M.E.: “High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis”. Proc. Natl. Acad. Sci. U. S. A., 1992, 89, 3070.

[7] Kuwano M., Toh S., Uchiumi T., Takano H., Kohno K., Wada M.: “Multidrug resistance-associated protein subfamily transporters and drug resistance”. Anticancer Drug Des., 1999, 14, 123.

[8] Tsuda H., Ito Y.M., Ohashi Y., Wong K.K., Hashiguchi Y., Welch W.R., et al.: “Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses”. Clin. Cancer Res., 2005, 11, 6880.

[9] Gram I.T., Lukanova A., Brill I., Braaten T., Lund E., Lundin E., et al.: “Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study”. Int. J. Cancer, 2012, 130, 2204.

[10] Mink P.J., Sherman M.E., Devesa S.S.: “Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978- 1998”. Cancer, 2002, 95, 2380.

[11] Mizuno M., Kikkawa F., Shibata K., Kajiyama H., Ino K., Kawai M., et al.: “Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary”. J. Surg. Oncol., 2006, 94, 138.

[12] Sung P.L., Chang Y.H., Chao K.C., Chuang C.M., Task Force on Systematic R.: “Meta-analysis of Ovarian C. Global distribution pattern of histological subtypes of epithelial ovarian cancer: a database analysis and systematic review”. Gynecol. Oncol., 2014, 133, 147.

[13] Pectasides D., Pectasides E., Psyrri A., Economopoulos T.: “Treatment issues in clear cell carcinoma of the ovary: a different entity?” Oncologist., 2006, 11, 1089.

[14] Omura G.A., Brady M.F., Homesley H.D., Yordan E., Major F.J., Buchsbaum H.J., Park R.C.: “Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience”. J. Clin. Oncol., 1991, 9, 1138.

[15] Pectasides D., Fountzilas G., Aravantinos G., Kalofonos C., Efstathiou H., Farmakis D., et al.: “Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience”. Gynecol. Oncol., 2006, 102, 285.

[16] Goff B.A., Sainz de la Cuesta R., Muntz H.G., Fleischhacker D., Ek M., Rice L.W., et al.: “Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease”. Gynecol. Oncol., 1996, 60, 412.

[17] Sugiyama T., Kamura T., Kigawa J., Terakawa N., Kikuchi Y., Kita T., et al.: “Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy”. Cancer, 2000, 88, 2584.

[18] Poorolajal J., Cheraghi Z., Irani A.D., Rezaeian S.: “Quality of Cohort Studies Reporting Post the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement”. Epidemiol. Health., 2011, 33, e2011005.

[19] Austin P.C.: “An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies”. Multivariate Behav. Res., 2011, 46, 399.

[20] Sturmer T., Joshi M., Glynn R.J., Avorn J., Rothman K.J., Schneeweiss S.: “A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods”. J. Clin. Epidemiol., 2006, 59, 437.

[21] Austin P.C.: “The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies”. Med. Decis. Making., 2009, 29, 661.

[22] Colombo P.E., Mourregot A., Fabbro M., Gutowski M., Saint-Aubert B., Quenet F., et al.: “Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients”. Eur. J. Surg. Oncol., 2009, 35, 135.

[23] Hoskins W.J., Bundy B.N., Thigpen J.T., Omura G.A.: “The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study”. Gynecol. Oncol., 1992, 47, 159.

[24] Thigpen J.T., Blessing J.A., Ball H., Hummel S.J., Barrett R.J.: “Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study”. J. Clin. Oncol., 1994, 12, 1748.

[25] Austin P.C.: “A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003”. Stat. Med., 2008, 27, 2037.

[26] Ming K., Rosenbaum P.R.: “Substantial gains in bias reduction from matching with a variable number of controls”. Biometrics, 2000, 56, 118.

[27] Sturmer T., Schneeweiss S., Brookhart M.A., Rothman K.J., Avorn J., Glynn R.J.: “Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly”. Am. J. Epidemiol., 2005, 161, 891.

[28] Austin P.C.: “The performance of different propensity score methods for estimating marginal hazard ratios”. Stat. Med., 2013, 32, 2837.

[29] Burger R.A., Brady M.F., Bookman M.A., Fleming G.F., Monk B.J., Huang H., et al.: “Incorporation of bevacizumab in the primary treatment of ovarian cancer”. N. Engl. J. Med., 2011, 365, 2473.

[30] Perren T.J., Swart A.M., Pfisterer J., Ledermann J.A., Pujade-Lauraine E., Kristensen G., et al.: “A phase 3 trial of bevacizumab in ovarian cancer”. N. Engl. J. Med., 2011, 365, 2484.

[31] Aghajanian C., Blank S.V., Goff B.A., Judson P.L., Teneriello M.G., Husain A., et al.: “OCEANS: a randomized, double-blind, placebocontrolled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer”. J. Clin. Oncol., 2012, 30, 2039.

[32] Pujade-Lauraine E., Hilpert F., Weber B., Reuss A., Poveda A., Kristensen G., et al.: “Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA openlabel randomized phase III trial”. J. Clin. Oncol., 2014, 32, 1302.

[33] Lim D., Oliva E.: “Precursors and pathogenesis of ovarian carcinoma”. Pathology, 2013, 45, 229.

[34] Yamaguchi K., Mandai M., Oura T., Matsumura N., Hamanishi J., Baba T., et al.: “Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes”. Oncogene, 2010, 29, 1741.

[35] Okamoto T., Mandai M., Matsumura N., Yamaguchi K., Kondoh H., Amano Y., et al.: “Hepatocyte nuclear factor-1beta (HNF-1beta) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma”. Mol. Carcinog., 2015, 54, 35.

[36] Matsumura N., Mandai M., Okamoto T., Yamaguchi K., Yamamura S., Oura T., et al.: “Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling”. Cancer Sci., 2010, 101, 2658.

[37] Albano J.D., Ward E., Jemal A., Anderson R., Cokkinides V.E., Murray T., et al.: “Cancer mortality in the United States by education level and race”. J. Natl. Cancer Inst., 2007, 99, 1384.

[38] Little R.J., Rubin D.B.: “Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches”. Annu. Rev. Public Health, 2000, 21, 121.

[39] Marcus S.M.: “Assessing non-consent bias with parallel randomized and nonrandomized clinical trials”. J. Clin. Epidemiol., 1997, 50, 823.

[40] Group GCIJGO [Internet]. Ovarian trial protocol version 3.1 (GCIG/JGOG3017) ; 2009. Available at: http://www.gcig.igcs.org/ files/JGOG3017_Protocol.pdf